SNPHF (Santen Pharmaceutical Co) Cyclically Adjusted Revenue per Share: $4.54 (As of Mar. 2026)


SNPHF Santen Pharmaceutical Co Ltd SNPHF
83 GF Score
Price $13.05
GF Value $10.24
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Santen Pharmaceutical Co SNPHF +4.40% 83 Cyclically Adjusted Revenue per Share is $4.54 as of Mar. 2026. GuruFocus rates SNPHF with a GF Score™ of 83/100 and a GF Value™ of $10.24 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Santen Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was $1.552. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.54 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Santen Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 6.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Santen Pharmaceutical Co was 10.70% per year. The lowest was 8.40% per year. And the median was 9.30% per year.

As of today (2026-07-12), Santen Pharmaceutical Co's current stock price is $13.05. Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $4.54. Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.87.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Santen Pharmaceutical Co was 5.62. The lowest was 1.77. And the median was 2.90.


Santen Pharmaceutical Co  (OTCPK:SNPHF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=13.05/4.54
=2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Santen Pharmaceutical Co was 5.62. The lowest was 1.77. And the median was 2.90.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.79 4.38 3.91 5.16 4.54

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.16 4.88 4.99 4.26 4.54

SNPHF vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SNPHF
83GF Score
Santen Pharmaceutical Co Ltd SNPHF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Santen Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.552/112.7000*112.7000
=1.552

Current CPI (Mar. 2026) = 112.7000.

Santen Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.142 98.100 1.312
201609 1.131 98.000 1.301
201612 1.114 98.400 1.276
201703 1.052 98.100 1.209
201706 1.237 98.500 1.415
201709 1.214 98.800 1.385
201712 1.255 99.400 1.423
201803 1.302 99.200 1.479
201806 1.257 99.200 1.428
201809 1.264 99.900 1.426
201812 1.285 99.700 1.453
201903 1.351 99.700 1.527
201906 1.367 99.800 1.544
201909 1.385 100.100 1.559
201912 1.455 100.500 1.632
202003 1.375 100.300 1.545
202006 1.337 99.900 1.508
202009 1.451 99.900 1.637
202012 1.513 99.300 1.717
202103 1.558 99.900 1.758
202106 1.474 99.500 1.670
202109 1.446 100.100 1.628
202112 1.470 100.100 1.655
202203 1.484 101.100 1.654
202206 1.231 101.800 1.363
202209 1.164 103.100 1.272
202212 1.359 104.100 1.471
202303 1.570 104.400 1.695
202306 1.369 105.200 1.467
202309 1.373 106.200 1.457
202312 1.507 106.800 1.590
202403 1.449 107.200 1.523
202406 1.314 108.200 1.369
202409 1.408 108.900 1.457
202412 1.410 110.700 1.435
202503 1.482 111.100 1.503
202506 1.399 111.700 1.412
202509 1.399 112.000 1.408
202512 1.415 113.000 1.411
202603 1.552 112.700 1.552

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $4.54 mean?
Santen Pharmaceutical Co (SNPHF) has a Cyclically Adjusted Revenue per Share of $4.54 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Santen Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $4.54. Overall, Santen Pharmaceutical Co has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share of $4.54 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $4.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.24, compared to a current price of $13.05 — trading 27.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $4.54. Santen Pharmaceutical Co's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Cyclically Adjusted Revenue per Share is $4.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 27.4% above its estimated GF Value™ of $10.24. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Cyclically Adjusted Revenue per Share: $4.54
  • GF Value™: $10.24 vs. price of $13.05 (27.4% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
83GF Score

Get the complete analysis for SNPHF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.24
GF Value